

TOTESD-29202860




FIGURE 1




FIGURE 2

FOIE50-29202860




FIGURE 3

FOUO-29204860

## 8,12 iPF<sub>2</sub> $\alpha$ -VI is increased in CSF from AD patients




FIGURE 4.

**8,12 iPF<sub>2</sub> $\alpha$ -VI is increased in urine from AD patients**




FIGURE 5

TOTEMO-29707860

**8,12 iPF<sub>2</sub> $\alpha$ -VI is increased in plasma from AD patients**




FIGURE 6

09870762.053101






FIGURE 7A

$iPF_{2\alpha}\text{-III}$   
(8-iso-PGF<sub>2α</sub>)



$iPF_{2\alpha}\text{-VI}$



8,12-iso- $iPF_{2\alpha}\text{-VI}$

FIGURE 7B

FIGURE 7C